IndustryCompany release

MannKind third-quarter revenue rises 24% to $101.9m on Furoscix ReadyFlow and paediatric Afrezza

🇺🇸 Mannkind Corp (MNKD) · Thu 05 Nov 2026

MannKind reported $45.0m in commercial product revenue, as the newly shipping Furoscix ReadyFlow and the paediatric Afrezza launch lifted sales, alongside early inhaled-pipeline data and a new licensing deal.

MannKind reported third-quarter 2026 results on 5 November, with total revenue of $101.9m, up 24% according to the company's headline. Commercial product revenue was $45.0m.

Furoscix ReadyFlow, which has FDA approval, began shipping in mid-September. By late October it accounted for about 75% of Furoscix shipments, indicating a rapid shift to the new presentation. Separately, the launch of Afrezza for paediatric patients lifted new prescriptions.

In the pipeline, MannKind said a Phase 1b study, INFLO-1, showed positive tolerability data for inhaled nintedanib (MNKD-201) in idiopathic pulmonary fibrosis (IPF). A global Phase 2 trial is now under way.

The company also announced a new licensing deal with Rose Pharma for an inhaled GLP-1 product. The summary available does not give financial terms or development timelines for the agreement.

What it means for your team

  • The fast uptake of Furoscix ReadyFlow shows how quickly a new presentation can replace an existing one, which matters for supply planning and product-transition management.
  • Pharmacovigilance teams may need to monitor post-launch safety reporting for the newly approved ReadyFlow and the paediatric Afrezza population.
  • The Phase 2 start for inhaled nintedanib in IPF and the Rose Pharma inhaled GLP-1 licence extend MannKind's inhaled-delivery portfolio; regulatory plans for both remain to be disclosed.

Company's press release (SEC filing): Mannkind Corp ↗

Article written by VigiEye from the official source (Mannkind Corp). Claims are the company's own. AI-assisted; check the source before acting.

More Industry All →